FRONTAGE (01521) Announces Annual Results: Shareholder Profit Surges 758.8% to $6.793 Million

Stock News

Mar 30

FRONTAGE (01521) has released its financial results for the year ended December 31, 2025. The group reported revenue of $257 million, representing a slight increase of 0.7% year-over-year. Profit attributable to the company's owners was $6.793 million, a significant surge of 758.8% compared to the previous year. Basic earnings per share stood at $0.0034.

According to the announcement, revenue from North American and European operations saw a minor decline, primarily due to a decrease in income generated from drug discovery services. This was negatively impacted by pharmaceutical and biotechnology companies continuing to optimize their research and development portfolios and maintaining cautious control over development expenditures. However, the decrease was partially offset by robust demand for laboratory testing services.

Revenue growth in the Chinese business was mainly driven by improved capacity utilization and the group's enhanced marketing efforts.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1138573984"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1138573984\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1138573984?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138573984","market":"us","top_or_hot":-1,"title":"FRONTAGE (01521) Announces Annual Results: Shareholder Profit Surges 758.8% to $6.793 Million","media":"Stock News","content":"<p>FRONTAGE (01521) has released its financial results for the year ended December 31, 2025. The group reported revenue of $257 million, representing a slight increase of 0.7% year-over-year. Profit attributable to the company's owners was $6.793 million, a significant surge of 758.8% compared to the previous year. Basic earnings per share stood at $0.0034.</p>\n<p>According to the announcement, revenue from North American and European operations saw a minor decline, primarily due to a decrease in income generated from drug discovery services. This was negatively impacted by pharmaceutical and biotechnology companies continuing to optimize their research and development portfolios and maintaining cautious control over development expenditures. However, the decrease was partially offset by robust demand for laboratory testing services.</p>\n<p>Revenue growth in the Chinese business was mainly driven by improved capacity utilization and the group's enhanced marketing efforts.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FRONTAGE (01521) Announces Annual Results: Shareholder Profit Surges 758.8% to $6.793 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFRONTAGE (01521) Announces Annual Results: Shareholder Profit Surges 758.8% to $6.793 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-30 19:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FRONTAGE (01521) has released its financial results for the year ended December 31, 2025. The group reported revenue of $257 million, representing a slight increase of 0.7% year-over-year. Profit attributable to the company's owners was $6.793 million, a significant surge of 758.8% compared to the previous year. Basic earnings per share stood at $0.0034.</p>\n<p>According to the announcement, revenue from North American and European operations saw a minor decline, primarily due to a decrease in income generated from drug discovery services. This was negatively impacted by pharmaceutical and biotechnology companies continuing to optimize their research and development portfolios and maintaining cautious control over development expenditures. However, the decrease was partially offset by robust demand for laboratory testing services.</p>\n<p>Revenue growth in the Chinese business was mainly driven by improved capacity utilization and the group's enhanced marketing efforts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"","article_id":"1138573984","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138573984","pubTimestamp":1774869975,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FRONTAGE (01521) has released its financial results for the year ended December 31, 2025. The group reported revenue of $257 million, representing a slight increase of 0.7% year-over-year. Profit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1141":"生命科学工具和服务","BK1576":"医药外包概念","01521":"方达控股","BK1583":"高瓴概念"},"translate_title":"方达(01521)公布全年业绩：股东溢利飙升758.8%至679.3万美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01521":1},"content_text":"FRONTAGE (01521) has released its financial results for the year ended December 31, 2025. The group reported revenue of $257 million, representing a slight increase of 0.7% year-over-year. Profit attributable to the company's owners was $6.793 million, a significant surge of 758.8% compared to the previous year. Basic earnings per share stood at $0.0034.\nAccording to the announcement, revenue from North American and European operations saw a minor decline, primarily due to a decrease in income generated from drug discovery services. This was negatively impacted by pharmaceutical and biotechnology companies continuing to optimize their research and development portfolios and maintaining cautious control over development expenditures. However, the decrease was partially offset by robust demand for laboratory testing services.\nRevenue growth in the Chinese business was mainly driven by improved capacity utilization and the group's enhanced marketing efforts.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}